Hematopoiesis News Volume 13.45 | Nov 15 2022

    By
    Jamie Kang
    -
    0
    21







    2022-11-15 | HN 13.45


    Hematopoiesis News by STEMCELL Technologies
    Vol. 13.45 – 15 November, 2022
    TOP STORY

    Myeloid-Derived Itaconate Suppresses Cytotoxic CD8+ T Cells and Promotes Tumor Growth

    Investigators discovered that myeloid-derived suppressor cells secreted itaconate that can be taken up by CD8+ T cells and suppressed their proliferation, cytokine production, and cytolytic activity.
    [Nature Metabolism]

    Abstract
    ON1045PSS-PSC-EDU-PSS-Course-sales-signature-728x90-1
    PUBLICATIONSRanked by the impact factor of the journal

    Adenine Base Editing Efficiently Restores the Function of Fanconi Anemia Hematopoietic Stem and Progenitor Cells

    Scientists developed a proof of concept therapeutic base editing strategy to address two of the most prevalent FANCA mutations in patient hematopoietic stem and progenitor cells.
    [Nature Communications]

    Full Article

    Base-Editing-Mediated Dissection of a γ-Globin Cis-Regulatory Element for the Therapeutic Reactivation of Fetal Hemoglobin Expression

    Researchers utilized base editing to generate a variety of mutations in the −200 region of the HBG promoters, including potent combinations of four to eight γ-globin-inducing mutations.
    [Nature Communications]

    Full Article

    VIP152 Is a Selective CDK9 Inhibitor with Pre-Clinical In Vitro and In Vivo Efficacy in Chronic Lymphocytic Leukemia

    In taking a multi-omic approach, scientists demonstrated that CDK9 inhibition with VIP152 disrupted the highly ordered assembly of the transcriptional machinery, thereby promoting cellular stress and inevitable cell death.
    [Leukemia]

    Full Article

    Curative Islet and Hematopoietic Cell Transplantation in Diabetic Mice without Toxic Bone Marrow Conditioning

    In diabetic mice, co-transplantation of donor-matched islets and hematopoietic cells durably corrected diabetes without chronic immunosuppression and no appreciable evidence of graft-versus-host disease.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Chronic Inflammation Decreases HSC Fitness by Activating the Druggable Jak/Stat3 Signaling Pathway

    Investigators used a mouse model of chronic multifocal osteomyelitis to assess the effects of a spontaneously developed inflammatory condition on HSCs.
    [EMBO Reports]

    Full ArticleGraphical Abstract

    T Cell and Cytokine Dynamics in the Blood of Patients after Hematopoietic Stem Cell Transplantation and Multipotent Mesenchymal Stromal Cells Administration

    Researchers studied the dynamics of memory T cells subpopulations and cytokines in the blood of allogeneic hematopoietic stem cell transplantation patients after mesenchymal stromal cell administration.
    [Transplantation and Cellular Therapy]

    Abstract

    Use of Eculizumab in Children with Allogeneic Hematopoietic Stem Cell Transplantation Associated Thrombotic Microangiopathy – a Multicentre Retrospective PDWP and IEWP EBMT Study

    A study by the Pediatric Diseases (PDWP) and Inborn Error Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) presented the response of 82 pediatric patients who developed transplantation-associated thrombotic microangiopathy and treated with eculizumab.
    [Bone Marrow Transplantation]

    Abstract

    Clinical Outcomes Associated with NPM1 Mutations in Patients with Relapsed or Refractory AML

    Scientists identified 206 patients with mutated Nucleophosmin 1 (NPM1) and compared their outcomes to 1516 patients with NPM1 wild-type. It was found that NPM1 mutational status had minimal impact on prognosis in relapsed or refractory AML.
    [Blood Advances]

    Abstract
    Listen to the Stem Cell Podcast episodes covering ISSCR 2022 sessions.
    REVIEWS

    Genetic Basis and Molecular Profiling in Myeloproliferative Neoplasms

    Investigators review the recent advances in the understanding of early events after the acquisition of a driver gene mutation that cause myeloproliferative neoplasms.
    [Blood]

    Abstract
    INDUSTRY AND POLICY NEWS

    SELLAS Life Sciences Announces Update on Phase III REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia

    SELLAS Life Sciences Group, Inc. announced important updates relating to its ongoing Phase III open-label registrational clinical trial for galinpepimut-S in AML patients who have achieved complete remission following second-line salvage therapy.
    [SELLAS Life Sciences Group, Inc.]

    Press Release

    Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

    Aptose Biosciences, Inc. announced the dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase Ia/b clinical trial in patients with relapsed or refractory AML.
    [Aptose Bioscience, Inc.]

    Press Release
    FEATURED EVENT

    2022 San Antonio Breast Cancer Symposium

    December 6 – 10, 2022
    San Antonio, Texas, United States

    > See All Events

    JOB OPPORTUNITIES

    Scientist – Hematological Cancers, Oncology Bioscience

    AstraZeneca – Waltham, Massachusetts, United States

    Faculty Position – Division of Hematology

    Washington University School of Medicine – St. Louis, Missouri, United States

    Co-Director – Pediatric Hematologic Malignancy Program

    Johns Hopkins School of Medicine – Baltimore, Maryland, United States

    PhD Studentship – Cancer Evolution

    German Cancer Research Center in the Helmholtz Association – Munich, Germany

    Senior Program Associate – Science in the City

    STEMCELL Technologies, Inc. – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter